Takeda turns to OTCs to bolster Japanese top line
This article was originally published in Scrip
Takeda has acquired exclusive distribution rights in Japan to seven over-the-counter (OTC) products currently sold by Johnson & Johnson KK Consumer Company, in a move apparently aimed at propping up Takeda's sales top line amid weakness in its domestic prescription business.
You may also be interested in...
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.
Full, planned acquisition of Tokyo-based operation will give US biotech giant a firmer foothold in key market and new platform for Otezla growth.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?